



Annual Report 2025

Our Trial Results Manuscripts

Clinical Research
for a Cure Tomorrow

[swisscancerinstitute-jahresbericht.ch](https://www.swisscancerinstitute-jahresbericht.ch)

Disease Group	Additional Disease Group	Type	Trial	Title	Authors	Journal	Impact factor
		Other		Chrono-immunotherapy as a low-hanging fruit for cancer treatment? A call for pragmatic randomized clinical trials	Özdemir BC, Bill R, Okyar A, Scheiermann C, Hayoz S, Olivier T	J IMMUNOTHER CANCER	10.3
		SCI services		Blastic plasmacytoid dendritic cell neoplasm: A Swiss case series of a very rare disease and a structured review of the literature	Meier-Lienhard R, Suter C, Pabst T, Hitz F, Passweg JR, Spertini O, Cantoni N, Betticher D, Simeon L, Medinger M, Hayoz S, Schmidt A	SWISS MED WKLY	4.2
Breast Cancers		Intergroup	IBCSG 18-98	Genomic characterization and prognostic significance of HER2-low, hormone receptor-positive, early breast cancers from the BIG 1-98 and SOFT clinical trials	Luen SJ, Brown LC, van Geelen CT, Savas P, Kammler R, Dell'Orto P, Biasi O, Coates AS, Gelber RD, Thuerlimann B, Colleoni M, Fleming GF, Francis PA, Regan MM, Viale G, Loi S	JCO PRECIS ONCOL	5.6
Breast Cancers		Intergroup	IBCSG 24-02	Assessment of Adjuvant Endocrine Therapy With Ovarian Function Suppression by Breast Cancer Index	O'Regan RM, Ren Y, Zhang Y, Siuliukina N, Schnabel CA, Kammler R, Viale G, Dell'Orto P, Munzone E, Láng I, Tondini C, Gomez HL, Chini C, Nicoletti SVL, Puglisi F, Zaman K, Goetz MP, Stearns V, Martino S, Salim M, Loibl S, Geyer CE, Bonnefoi HR, Ciruelos EM, Loi S, Colleoni M, Fleming GF, Francis PA, Walley BA, Pagani O, Treuner K, Regan MM	JAMA NETW OPEN	9.7
Breast Cancers		Intergroup	IBCSG 25-02	Prognostic value of patient-reported depression in women with hormone-responsive early breast cancer in TEXT and SOFT	Ribi K, Cole BF, Fleming GF, Walley BA, Francis PA, Abdi E, Burstein HJ, Cheng KL, Chia SKL, Dakhil SR, Davidson NE, Della-Fiorentina SA, Frith AE, Levine E, Lupichuk S, Pritchard K, Salim M, Stearns V, Stewart J, Valero V, van der Westhuizen A, Pagani O, Loi S, Colleoni M, Gelber RD, Goldhirsch A, Coates AS, Regan MM, Bernhard J	CANCER	5.1
Breast Cancers		Intergroup	IBCSG 35-07	Prognostic relation of body mass index on extended aromatase inhibition treatment in postmenopausal patients with estrogen receptor positive breast cancer: A retrospective analysis of the SOLE trial	Biganzoli G, Richard F, Isnaldi E, Marano G, Boracchi P, Maetens M, Floris G, Neven P, Jerusalem G, Munzone E, Hitre E, Gombos A, Thompson A, Aebi S, Kammler R, Dell'Orto P, Viale G, Regan MM, Colleoni M, Biganzoli E, Desmedt C	EUR J CANCER	7.1
Breast Cancers		Intergroup	IBCSG 48-14 POSITIVE	Breastfeeding after hormone receptor-positive breast cancer: Results from the Positive Trial	Peccatori FA, Niman SM, Partridge AH, Ruggeri M, Colleoni M, Saura C, Shimizu C, Saetersdal AB, Kroep JR, Gelmon K, Amant F, Mailliez A, Moore HCF, Ruiz-Borrego M, Walshe JM, Borges VF, Gombos A, Kataoka A, Rousset-Jablonski C, Borstnar S, Takei J, Lee JE, Saunders C, Bjelic-Radisic V, Susnjar S, Cardoso F, Klar NJ, Ferreiro T, El-Abed S, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O, Azim HA Jr	J CLIN ONCOL	41.9

Disease Group	Additional Disease Group	Type	Trial	Title	Authors	Journal	Impact factor
Breast Cancers		Intergroup	IBCSG 48-14 POSITIVE	Hormonal factors predictive of fertility in patients with breast cancer interrupting adjuvant endocrine therapy to attempt pregnancy in POSITIVE trial	Demeestere I, Niman SM, Partridge AH, Diego DS, Kammler R, Ruggeri M, Colleoni M, Shimizu C, Saura C, Gelmon KA, Saetersdal AB, Kroep JR, Mailliez A, Amant F, Ruiz-Borrego M, Lee JE, Kataoka A, Walshe JM, Takei J, Borstnar S, Borges VF, Saunders C, Susnjar S, Bjelic-Radisc V, Cardoso F, Meisel JL, Kawwass JF, Spanic T, El-Abed S, Piccart M, Korde LA, Goldhirsch A, Gelber RD, Pagani O, Azim HA Jr, Peccatori FA	BREAST	7.9
Breast Cancers		Intergroup	IBCSG 52-15 PALLAS	Palbociclib with adjuvant endocrine therapy in early breast cancer: 5-year follow-up analysis of the global multicenter, open-label, randomized phase III PALLAS trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13)	Mayer EL, Hlauschek D, Gnant M, O'Brien PJ, Bellet-Ezquerria M, Goetz MP, Ruiz-Borrego M, Chan A, Clifton K, Egle D, Lake D, Cabrera P, Mamounas T, Pristauz-Telsnigg G, Dayao Z, Gil M, Cameron D, Traina T, Morris P G, Sabanathan D, Rinnerthaler G, Meisel J, Prat A, Wolff AC, Tseng LM, Isaacs C, Singer CF, Rubovszky G, Foukakis T, Jassem J, Winer EP, Vetter M, Federmann J, Metzger O, Schurmans C, Gauthier E, Lu D R, Fesl C, Dueck A, DeMichele A	ANN ONCOL	65.4
Breast Cancers		Intergroup	IBCSG 55-17 TOUCH	Palbociclib plus letrozole versus weekly paclitaxel, both in combination with trastuzumab plus pertuzumab, as neoadjuvant treatment for patients with HR+/HER2+ early breast cancer: primary results from the randomized phase II TOUCH trial (IBCSG 55-17)	Malorni L, Tyekuceva S, Gombos A, Hasler-Stub U, Zamgani C, Chakiba-Brugere, Colleoni M, Mueller A, Minisini AM, Taylor D, Salmon JP, Gallerani E, Cariello A, Fontana A, Roschitzki-Voser H, Kammler R, Rueep B, Loi S, Viale G, Regan MM, Brain E, Biganzoli L	ANN ONCOL	65.4
Breast Cancers		Secondary	SAKK 21/12	Final overall survival analysis of the phase II SAKK 21/12 trial of transdermal CR1447 in patients with metastatic breast cancer	Vetter M, Holer L, Rothgiesser K, Schönfeld W, Riniker S, von Moos R, Trojan A, Kralidis E, Rabaglio M, Fehr MK, Müller A, Borner M, Rossi L, Kurzeder C, Thürlimann B	CLIN BREAST CANCER	2.7
Breast Cancers	Surgery	Secondary	SAKK 23/16	Genomic profiling of primary tumor and lymph node metastasis in patients with clinically node-positive breast cancer: prospective cohort study within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)	Knauer M, Egle D, Hayoz S, Sávolt Á, Tausch C, Bucher S, Simonson C, Satler R, Heil J, Bekes I, Bjelic-Radisc V, Audeh W, Lam GT, Menicucci A, Muenst S, Ostapenko V, Kurzeder C, Heidinger M, Weber WP	EUR J CANCER	7.1
Developmental Therapeutics		Meta-analysis	phase-1_retrospective data analysis	A retrospective analysis of Phase I and Phase I/II clinical trials conducted by the Swiss Group for Clinical Cancer Research (SAKK)	Koster KL, Colombo I, Hayoz S, Eckhardt K, Rojas Mora A, Hess D, Britschgi C, Haefliger S, Imbimbo M, Bertoni F, Homicsko K, von Moos R, Sessa C, Joerger M, Stathis A	ESMO OPEN	8.3

Disease Group	Additional Disease Group	Type	Trial	Title	Authors	Journal	Impact factor
Developmental Therapeutics	Cancers of Head and Neck	Primary	SAKK 11/16	Overall survival of recurrent/metastatic head & neck squamous cell carcinoma patients progressing after = 1 line of systemic therapy, treated with MVX-ONCO-1, a novel, first in class cell encapsulation-based immunotherapy: results of SAKK 11/16, a phase IIa trial	Fernandez E, Vernet R, Urwyler M, Von Rohr O, Charrier E, Belkouch MC, Saingier V, Courtout F, DeVito C, Ancrenaz V, Dulguerov N, Karenovics W, Grogg J, Renaux J, Gobat K, Müller G, Brezina T, Rordorf T, Joerger M, Michielin O, Villard J, Mach N	EXP HEMATOL ONCOL	13.5
Developmental Therapeutics	Breast Cancers	Primary	SAKK 65/16	TLD-1, a novel liposomal doxorubicin, in patients with solid tumors: Comparative pharmacokinetics and final results of a multicenter phase 1 study (SAKK 65/16)	Klose M, Colombo I, Gobat K, Koster K, Haefliger S, Rabaglio M, Bastian S, Schwitter M, Zürrer-Härdi U, Eckhardt K, Hayoz S, Halbherr S, Sessa C, Michelet R, Mc Laughlin AM, Hess D, Stathis A, Kloft C, Joerger M	CLIN PHARMA-COKINET	4.8
Developmental Therapeutics		Secondary	SAKK 80/19_Al-pineTIR	Unsupervised dynamic ePRO reporting of immunotherapy related symptoms in cancer patients	Stauffacher AK, von Stockar L, Witschel HF, Hayoz S, Petrasch U, Schmid T, Jakob A, Kullak-Ublick GA, Trojan A	ONCOLOGY	1.8
Gastrointestinal Cancers		Meta-analysis	SAKK 75/08	Evaluation of pathological complete response as a surrogate endpoint for overall survival in resectable esophageal cancer	Okui J, Nagashima K, Matsuda S, Sato Y, Kawakubo H, Ruhstaller T, Thuss-Patience P, Nilsson M, Klevebro F, Tan L, Zhang S, Aparicio T, Piessen G, van der Zijden C, Mostert B, Wijnhoven BPL, Tsushima T, Takeuchi H, Kato K, Kitagawa Y	BRIT J SURG	8.8
Gastrointestinal Cancers		Meta-analysis	SAKK 75/08	Recurrence-free Survival as a Surrogate Endpoint for Overall Survival in Resectable Esophageal Cancer: Integrated Analysis of Individual Patient Data From Phase III Trials	Okui J, Matsuda S, Nagashima K, Sato Y, Kawakubo H, Ruhstaller T, Thuss-Patience P, Nilsson M, Klevebro F, Tan L, Zhang S, Aparicio T, Piessen G, van der Zijden C, Mostert B, Wijnhoven BPL, Tsushima T, Takeuchi H, Kato K, Kitagawa Y	ANN SURG	6.4
Gastrointestinal Cancers		Primary	SAKK 41/13	Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients – The Phase III, Prospective-Randomized Placebo-Controlled Multicenter SAKK 41/13 Trial	Güller U, Hayoz S, Horber D, Jochum W, De Dosso S, Koeberle D, Schacher S, Inauen R, Stahl M, Delaunoit T, Ettrich T, Bodoky G, Michel P, Koessler T, Rothgiesser K, Calmonte S, Joerger M	CLIN CANCER RES	10.4
Gynecological Cancers		Intergroup	Ago-Ovar_2.29	Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III Trial	Harter P, Marme F, Redondo A, Reuss A, Lindemann K, Kurzeder C, Van Nieuwenhuysen E, Marth C, Pietzner K, Ray-Coquard I, Garcia-Duran C, Jonuskiene G, Heitz F, Bellier C, Pérez-Fidalgo J, El-Balat A, Selle F, Romero I, Wimberger P, Follana P, Pardo B, de Gregorio N, Joly F, Gaba L, Burges A, Fabbro M, Hasenburg A, Fehm T, Schmalfeldt B, Pautier P	J CLIN ONCOL	41.9

Disease Group	Additional Disease Group	Type	Trial	Title	Authors	Journal	Impact factor
Leukemias		Intergroup	CLL 17	Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia	Al-Sawaf O, Stumpf J, Zhang C, Simon F, Bosch F, Feyzi E, Ghia P, Gregor M, Kater AP, Lindström V, Mattsson M, Niemann CU, Staber PB, Tadmor T, Thornton P, Wendtner CM, Janssens A, Noesslinger T, Bohn JP, da Cunha-Bang C, Poulsen CB, Ranti J, Illmer T, Schoettker B, Böttcher S, Gaska T, Vandenberghe E, Clifford R, Benjamini O, Frustaci AM, Scarfò L, Sportoletti P, Schreurs J, Levin MD, van der Straaten H, van der Klift M, Tran H, de la Serna J, Loscertales J, Lindblad O, Bergendahl Sandstedt A, Goede J, Baumann M, Fink AM, Fischer K, Ritgen M, Kreuzer KA, Schneider C, Tausch E, Stilgenbauer S, Robrecht S, Eichhorst B, Hallek M	NEW ENGL J MED	78.5
Leukemias		Intergroup	HOVON 103	Comparability of external and internal control patients for the prospective randomized HOVON-103 trial in older AML patients	Hermans SJF, Versluis J, van Werkhoven ED, van Norden Y, Janssen JJWM, Huls GA, Pabst T, Breems DA, Berkx E, Dinmohamed AG, Huijgens PC, Sträng E, Hernández Rivas JM, Sobas M, Ayala Diaz R, Martinez Lopez J, Metzeler KH, Haferlach T, Thiede C, Uyl-de Groot CA, Bullinger L, Löwenberg B, Ossenkoppele GJ, Pignatti F, Cornelissen JJ	BRIT J HAEMATOL	3.8
Leukemias		Intergroup	HOVON 132	Computational measurable residual disease assessment in acute myeloid leukemia: a retrospective validation in the HOVON-SAKK-132 trial	Mocking TR, Haaksma LH, Reuvekamp T, Kelder A, Scholten WJ, Ngai LL, Breems DA, Fischer T, Gjertsen BT, Griškevičius L, Juliusson G, Maertens JA, Manz MG, Pabst T, Passweg JR, Porkka K, Valk PJM, Gradowska P, Löwenberg B, de Leeuw DC, Janssen JJWM, Ossenkoppele GJ, van de Loosdrecht AA, Cloos J, Bachas C	LEUKEMIA	12.8
Leukemias		Intergroup	HOVON 132	Different features of acute myeloid leukemia stem cell quantification in intensively treated patients	Ngai LL, Reuvekamp T, Hanekamp D, Janssen F, Marsbergen LO, Carbaat-Ham J, Hofland MAM, Fayed MMHE, Kelder A, Scholten WJ, Snel AN, Bachas C, Tettero JM, Breems DA, Fischer T, Gjertsen BT, Griškevičius L, Juliusson G, Van de Loosdrecht AA, Maertens JA, Manz MG, Pabst T, Passweg JR, Porkka K, Valk PJM, Gradowska P, Löwenberg B, Ossenkoppele GJ, De Leeuw DC, Cloos J	HAEMATOLOGICA	8.2

Disease Group	Additional Disease Group	Type	Trial	Title	Authors	Journal	Impact factor
Leukemias		Intergroup	HOVON 42, HOVON 42A, HOVON 43, HOVON 81, HOVON 92, HOVON 102, HOVON 103, HOVON 132	An Improved Prognostic Model for Patients with Acute Myeloid Leukemia and First Relapse	van der Maas NG, Breems D, Klerk CPW, Pabst T, Gradowska P, Thomas A, Biemond BJ, Kuball J, Van Elssen CHMJ, Visser O, Vekemans MC, Graux C, Maertens J, Knapper S, Dennis M, Freeman S, Thomas I, Beverloo HB, Huls G, Craddock C, Valk PJM, Vyas P, Russell N, Ossenkoppele G, Löwenberg B, Cornelissen JJ, Versluis J	BLOOD ADV	7.4
Leukemias		Primary	SAKK 34/17	Ibrutinib Lead-in followed by Venetoclax Plus Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia - SAKK 34/17	Condoluci A, Romano I, Dietrich D, Pini K, Stüssi G, Müller G, Cantoni N, Cathomas R, Mey U, Widmer A, Zenz T, Gregor M, Heim D, Andres M, Benz R, Rossi D	BLOOD	21
Leukemias		SCI services		Prognostic impact of the AML60+ score for elderly patients with acute myeloid leukemia treated with hypomethylating agents – a retrospective multicentric analysis	Petermilch V, Fuchs S, Weber M, Gobat K, Micheloud C, Graf L, Gerth Y, Goede J, Lehmann T, Driessen C, Mey UJM, Cathomas R, Cogliatti S, Silzle T	CANCERS	4.4
Lung Cancers		Intergroup	ETOP BEAT-meso	A randomised phase III study of bevacizumab and carboplatin-pemetrexed chemotherapy with or without atezolizumab, as first-line treatment for advanced pleural mesothelioma: results of the ETOP 13 18 BEAT-meso trial	Felip E, Popat S, Dafni U, Ribi K, Pope A, Cedres S, Shah R, de Marinis F, Cove Smith L, Bernabé R, Früh M, Nackaerts K, Greillier L, Scherz A, Massuti B, Nadal E, Vila Martinez L, Talbot T, Roschitzki-Voser H, Dimopoulou G, Schär S, Ruepp B, Savic S, Peters S, Stahel R	ANN ONCOL	65.4
Lung Cancers		Meta-analysis	SAKK 16/96, SAKK 16/00, SAKK 16/01, SAKK 16/08, SAKK 16/14	Outcomes in patients with resectable stage III NSCLC who did not have definitive surgery after neoadjuvant treatment: Retrospective analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14.	Raimann S, Schär S, Hayoz S, Guckenberger M, Finazzi T, Opitz I, Schmid S, Mark M, Addeo A, Mauti LA, Betticher DC, Ris HB, Stupp R, Curioni-Fontecedro A, Peters S, Früh M, Rothschild SI, Pless M, König D	JTO CLIN RES REP	3
Lung Cancers		Meta-analysis	SAKK 16/96, SAKK 16/00, SAKK 16/01, SAKK 16/08, SAKK 16/14	Sex specific efficacy and safety outcomes in operable Stage III Non-Small Cell Lung Cancer (NSCLC): pooled analysis of the SAKK trials 16/96, 16/00, 16/01, 16/08 and 16/14	Frehner L, Schär S, Hayoz S, Guckenberger M, Finazzi T, Mark M, Addeo A, Mauti LA, Betticher D, Stupp R, Curioni-Fontecedro A, Peters S, Früh M, Rothschild SI, Pless M, König D, Opitz I, Ris HB, Özdemir BC, Schmid S	ESMO OPEN	8.3
Lung Cancers		Other		Lung Cancer Research from the Swiss Cancer Institute: ELCC 2025 Highlights	Rothschild SI, Waibel C, König D, Hayoz S, Mauti LA	healthbook TIMES Oncology Hematology	
Lung Cancers	Radio-Oncology	Primary	SAKK 15/19	Thoracic radiotherapy plus maintenance Durvalumab after first line Carboplatin and Etoposide plus Durvalumab in extensive-stage disease small cell lung cancer (ES-SCLC) – a multicenter single arm open label phase II trial (SAKK 15/19)	Addeo A, Dietrich D, Mach N, Mark MT, Joerger M, Froesch P, Imbimbo M, König D, Fernandez E, Patzen A, Veas H, Picardi C, Früh M	EUR J CANCER	7.1

Disease Group	Additional Disease Group	Type	Trial	Title	Authors	Journal	Impact factor
Lung Cancers		SCI services		First-line immunotherapy +/- chemotherapy with or without upfront stereotactic radiosurgery in patients with Non-Small Cell Lung Cancer (NSCLC) with asymptomatic brain metastases	Frehner L, Schär S, Hayoz S, Petermichl V, Speicher P, I Rothschild S, Mauti LA, König D, Finazzi T, Froesch P, Marini S, Allemann A, Mark M, Janthur WD, Stamatiou A, Metaxas Y, Ermis E, Wagner F, Früh M, Schmid S	LUNG CANCER	4.4
Lung Cancers		Secondary	SAKK 16/14	Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy	Schmid D, Sobottka B, Manzo M, Trüb M, Leonards K, Herzig P, Oyewole OR, Jermann P, Hayoz S, Savic Prince S, Tochtermann G, Natoli M, Pless M, Bettini A, Früh M, Mauti LA, Britschgi C, Peters S, Mark M, Ochsenbein AF, Janthur WD, Waibel C, Mach N, Froesch P, Buess M, Bohanes P, Gonzalez M, Alborelli I, Rothschild SI, Koelzer VH, Zippelius A	NAT COMMUN	15.7
Lymphomas		Intergroup	HD 21	Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multi-centre, randomised, parallel, open-label, phase 3 HD21 trial	Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M, Schaub V, Hüttmann A, Keil F, Dierlamm J, Hänel M, Novak U, Meissner J, Hellmuth JC, Mathas S, Zijlstra JM, Fosså A, Viardot A, Hertenstein B, Martin S, Giri P, Kamper P, Molin D, Jablonski J, Damaschin C, Robertz AS, Rosenbrock J, Fuchs M, Borchmann P, Behringer K	LANCET ONCOL	35.9
Lymphomas		Intergroup	HD 21	Positron Emission Tomography-Guided Brentuximab Vedotin, Etoposide, Cyclophosphamide, Doxorubicin, Dacarbazine, and Dexamethasone in Older Patients With Advanced-Stage Classic Hodgkin Lymphoma: A Prospective, Multicenter, Ingle-Arm, Phase II Cohort of the German Hodgkin Study Group HD21 Trial	Ferdinandus J, Kaul H, Fosså A, Hüttmann A, Keil F, Ko YD, Hitz F, Schwarz M, Trenker C, Kerkhoff A, Staib P, Wille K, Dresel I, Hahn D, Hertenstein B, Moosmann P, Mey U, Balabanov S, Armytage T, Roncolato F, Hellmuth JC, Hertzberg M, Kobe C, Klapper W, Baues C, Eich HT, Kreissl S, Fuchs M, Jablonski J, Schneider G, Tharmaseelan H, Eichenauer DA, von Tresckow B, Borchmann P, Bröckelmann PJ	J CLIN ONCOL	41.9
Lymphomas		Secondary	SAKK 35/10	Rituximab-Lenalidomide as frontline therapy in Follicular Lymphoma Patients: a 10-year Update of the SAKK 35/10 Randomized Trial	Kimby EK, Schär S, Pirova MC, Vanazzi A, Mey UJM, Rauch D, Wahlin BE, Hitz F, Hernberg M, Johansson AS, de Nully Brown P, Hagberg H, Ferreri AJMJ, Krasniqi F, Voegeli M, Novak U, Zander T, Bersvendsen H, Mamot C, Mingrone W, Stathis A, Dirnhofer S, Hayoz S, Østenstad B, Zucca E	BLOOD ADV	7.4

Disease Group	Additional Disease Group	Type	Trial	Title	Authors	Journal	Impact factor
Urogenital Cancers		Intergroup	STAMPEDE	Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol	Gillessen S, Murphy L, James ND, Sachdeva A, El-Taji O, Abdel-Aty H, Adler AI, Amos C, Attard G, Varughese M, Gale J, Brown S, Srihari N, Birtle AJ, Brown M, Chan K, Chowdhury S, Cross W, Dearnaley DP, Din O, Dutey-Magni P, Gilbert DC, Gilson C, Gray S, Grist E, Hofmann U, Hudson AM, Jain Y, Jeyasangar G, Jones R, Kayani M, Langley RE, Malik Z, Mason MD, Matheson D, McAlpine C, Macnair A, Millman R, Murphy C, Padden-Modi M, Parikh O, Parker C, Rush H, Russell M, Srinivasan R, Sundar S, Tanguay JS, Turco F, Williams P, Sydes MR, Parmar MKB, Brown LC, Clarke NW	LANCET ONCOL	35.9
Urogenital Cancers		Secondary	SAKK 09/10	Long-term urinary continence and influencing factors after salvage radiotherapy: Results of the SAKK 0910 dose escalation trial	Schröder C, Zwahlen DR, Schär S, Hölscher T, Arnold W, Polat B, Hildebrandt G, Müller AC, Putora PM, Papachristofilou A, Schär C, Hayoz S, Sumila M, Zaugg K, Guckenberger M, Ost P, Bosetti DG, Reuter C, Gomez S, Khanfir K, Beck M, Riesterer O, Thalmann GN, Aebersold DM, Ghadjar P	RADIOTHER ONCOL	4.9
Urogenital Cancers		Secondary	SAKK 09/10	Predicting Dose-Response to Prostate Cancer Radiotherapy: Validation of a Radiation Signature in the Randomized Phase III NRG/RTOG 0126 and SAKK 09/10 Trials	Dal Pra A, Ghadjar P, Ryu HM, Proudfoot JA, Hayoz S, Michalski JM, Spratt DE, Liu Y, Schär C, Berlin AM, Zwahlen DR, Simko JP, Hölscher T, Efsthathiou JA, Polat B, Sandler HM, Hildebrandt G, Parliament MB, Mueller AC, Dayes IS, Plasswilm L, Correa RJM, Robertson JM, Karrison TG, Davicioni E, Hall WA, Feng FY, Pollack A, Thalmann GN, Nguyen PL, Aebersold DM, Tran PT, Zhao SG	ANN ONCOL	65.4